MX2017014080A - Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. - Google Patents

Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.

Info

Publication number
MX2017014080A
MX2017014080A MX2017014080A MX2017014080A MX2017014080A MX 2017014080 A MX2017014080 A MX 2017014080A MX 2017014080 A MX2017014080 A MX 2017014080A MX 2017014080 A MX2017014080 A MX 2017014080A MX 2017014080 A MX2017014080 A MX 2017014080A
Authority
MX
Mexico
Prior art keywords
bacterial infections
preventing
heterocyclic compounds
treating bacterial
compounds
Prior art date
Application number
MX2017014080A
Other languages
English (en)
Inventor
Le Strat Fródóric
Chasset Sophie
Chevreuil Francis
Ledoussal Benoit
Barbion Julien
Brias Julie
Caravano Audrey
Faivre Fabien
Vomscheid Sophie
Simon Christophe
Lecointe Nicolas
RICHARD Sóbastien
Le Fralliec Góraldine
Briet Sophia
Oliveira Chrystelle
Original Assignee
Mutabilis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15305701.3A external-priority patent/EP3091018A1/en
Application filed by Mutabilis filed Critical Mutabilis
Publication of MX2017014080A publication Critical patent/MX2017014080A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a compuestos heterocí­clicos, su procedimiento de preparación, composiciones farmacóuticas que comprenden estos compuestos y el uso de las mismas, opcionalmente en combinación con otros agentes antibacterianos y/o compuestos beta-lactámicos, para la prevención o tratamiento de las infecciones bacterianas. La presente invención también se refiere al uso de estos compuestos como inhibidores de íŸ-lactamasa y/o como agentes antibacterianos.
MX2017014080A 2015-05-07 2016-05-06 Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. MX2017014080A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305701.3A EP3091018A1 (en) 2015-05-07 2015-05-07 Heterocyclic compounds and their use in preventing or treating bacterial infections
EP16305144 2016-02-08
PCT/EP2016/060142 WO2016177862A1 (en) 2015-05-07 2016-05-06 Heterocyclic compounds and their use in preventing or treating bacterial infections

Publications (1)

Publication Number Publication Date
MX2017014080A true MX2017014080A (es) 2018-07-06

Family

ID=56083989

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014080A MX2017014080A (es) 2015-05-07 2016-05-06 Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.

Country Status (13)

Country Link
US (1) US10183943B2 (es)
EP (1) EP3292125B1 (es)
JP (1) JP6767392B2 (es)
KR (1) KR20180002650A (es)
CN (1) CN107580595B (es)
AU (1) AU2016257338B2 (es)
BR (1) BR112017023359A2 (es)
CA (1) CA2983674A1 (es)
CL (1) CL2017002803A1 (es)
MX (1) MX2017014080A (es)
RU (1) RU2741496C2 (es)
TW (1) TWI754613B (es)
WO (1) WO2016177862A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170014135A1 (en) 2015-07-14 2017-01-19 Keith Edward Martin Surgical tool
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3300736B1 (en) * 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
PT2872510T (pt) * 2011-08-30 2017-03-01 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infeções bacterianas
TW201343645A (zh) * 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP2855441B1 (en) 2012-06-04 2018-04-11 elkimia inc. Imino compounds as protecting agents against ultraviolet radiations
US20140315876A1 (en) * 2013-03-15 2014-10-23 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP2016538258A (ja) * 2013-10-22 2016-12-08 ウォックハート リミテッド 抗菌剤を含む医薬組成物
CN107531708A (zh) * 2015-03-31 2018-01-02 拜欧蒂姆公司 新型杂环化合物及它们在预防或治疗细菌感染中的应用

Also Published As

Publication number Publication date
CA2983674A1 (en) 2016-11-10
RU2017135321A (ru) 2019-04-10
RU2017135321A3 (es) 2019-08-13
WO2016177862A1 (en) 2016-11-10
US20180093985A1 (en) 2018-04-05
TW201643165A (zh) 2016-12-16
JP2018515504A (ja) 2018-06-14
CN107580595A (zh) 2018-01-12
JP6767392B2 (ja) 2020-10-14
CL2017002803A1 (es) 2018-05-11
KR20180002650A (ko) 2018-01-08
CN107580595B (zh) 2020-09-18
AU2016257338B2 (en) 2020-03-05
BR112017023359A2 (pt) 2018-07-17
EP3292125A1 (en) 2018-03-14
TWI754613B (zh) 2022-02-11
EP3292125B1 (en) 2019-09-04
AU2016257338A1 (en) 2017-10-26
RU2741496C2 (ru) 2021-01-26
US10183943B2 (en) 2019-01-22

Similar Documents

Publication Publication Date Title
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
WO2013122888A3 (en) Methods of treating bacterial infections
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
WO2015003816A3 (en) Cystobactamides
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX363678B (es) Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
MX2016009248A (es) Compuestos que contienen nitrogeno y su uso como agentes antibacterianos.
SG11201608441YA (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
PH12016501988A1 (en) Antibacterial compounds
ZA202002093B (en) Antibacterial compounds
MX2017012073A (es) Compuestos de minociclina para biodefensas.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX2017012539A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2018011095A (es) Compuestos de carbapenem.
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
PH12015500518A1 (en) Tricyclic tetrahydroquinoline antibacterial agents
WO2015035234A3 (en) Anti-microbial compounds and compositions